Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Ohara Obtains Exclusive Rights to Biliary Tract Cancer Drug
Ohara Pharmaceutical said on April 25 that it has entered into a license and joint development agreement with drug discovery biotech J-Pharma for its biliary tract cancer treatment JPH203. The agreement gives Ohara exclusive rights to research, develop, market, and…
To read the full story
Related Article
- J-Pharma’s Biliary Tract Cancer Med Hits Mark in Japan PII Study
January 24, 2023
- Ohara Licenses Novel Glioma Treatment from US Pharma Aiming to Bolster Pediatric Pipelines
February 18, 2019
- Generic Player Ohara Looks to Morph into Innovative Drug Maker, with Focus on Oncology
February 13, 2019
- J-Pharma Initiates PI Trial of LAT1 Inhibitor
February 23, 2015
BUSINESS
- Sumitomo Flags Diabetes Pipeline Gap as Key Strategic Issue: CEO
February 2, 2026
- Astellas, MSD Seek Japan Nod for Padcev/Keytruda in Perioperative MIBC
February 2, 2026
- Alfresa Launches End-to-End Platform to Support Biotech Entry into Japan
February 2, 2026
- Nichi-Iko’s Xarelto Generic Adds VTE Use
February 2, 2026
- Ohara Files Japan NDA for Jazz’s Diffuse Midline Glioma Drug
February 2, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…